Cardlytics Inc (NASDAQ:CDLX)’s traded shares stood at 0.44 million during the last session, with the company’s beta value hitting 1.53. At the close of trading, the stock’s price was $3.95, to imply an increase of 3.13% or $0.12 in intraday trading. The CDLX share’s 52-week high remains $20.52, putting it -419.49% down since that peak but still an impressive 26.84% since price per share fell to its 52-week low of $2.89. The company has a valuation of $200.75M, with an average of 0.67 million shares in intraday trading volume over the past 10 days and average of 760.17K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Cardlytics Inc (CDLX), translating to a mean rating of 3.17. Of 3 analyst(s) looking at the stock, 1 analyst(s) give CDLX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.2.

Cardlytics Inc (NASDAQ:CDLX) trade information

After registering a 3.13% upside in the last session, Cardlytics Inc (CDLX) has traded red over the past five days. The 5-day price performance for the stock is -2.95%, and -24.18% over 30 days. With these gigs, the year-to-date price performance is -57.11%. Short interest in Cardlytics Inc (NASDAQ:CDLX) saw shorts transact 7.19 million shares and set a 7.82 days time to cover.

The extremes give us $3.5 and $5 for target low and target high price respectively. As such, CDLX has been trading -26.58% off suggested target high and 11.39% from its likely low.

Cardlytics Inc (CDLX) estimates and forecasts

Looking at statistics comparing Cardlytics Inc share performance against respective industry, we note that the company has underperformed competitors. Cardlytics Inc (CDLX) shares are -54.70% down over the last 6 months, with its year-to-date growth rate lower than industry average at -109.68% against 16.40%. The rating firms project that company’s revenue will shrink -13.35% compared to the previous financial year.

Revenue forecast for the current quarter as set by 5 analysts is 63.45M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 61.87M.Earnings reports from the last fiscal year show that sales brought in 89.17M and 67.61M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -28.84% before dropping -8.49% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -5.75% for the past 5-year period. While 2024 is set for a -10.30% return in earnings, projections for the next 5 years are at 44.10% annually.

CDLX Dividends

Cardlytics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Cardlytics Inc (NASDAQ:CDLX)’s Major holders

Cardlytics Inc insiders hold 5.14% of total outstanding shares, with institutional holders owning 61.52% of the shares at 64.85% float percentage. In total, 61.52% institutions holds shares in the company, led by CAS INVESTMENT PARTNERS, LLC. As of 2024-06-30, the company held over 6.46 million shares (or 14.9483% of shares), all amounting to roughly $53.08 million.

The next major institution holding the largest number of shares is BLACKROCK INC. with 3.15 million shares, or about 7.2876% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $25.88 million.